Cross-National Psychedelic Use Study: ICPS Findings

Introduction to the ICPS Study

The 2023 International Cannabis Policy Study (ICPS) has provided new insights into the nonmedical and medical use of psychedelic drugs across several countries, including Canada, the United States, Australia, and New Zealand. This cross-national study, published in June 2026, reveals a significant consumer interest in the therapeutic potential of psychedelics like psilocybin, LSD, MDMA, and ketamine. However, the study also highlights a concerning trend: many individuals are using these substances without medical supervision, potentially leading to adverse health effects.

Mechanisms and Context

The ICPS study employed repeated cross-sectional surveys to gather self-reported data on the use of psychedelics. Participants were asked about their lifetime, past year, and past month use of these substances, as well as their discussions with medical professionals regarding medical use and any adverse events experienced. The findings suggest that psilocybin is the most commonly used psychedelic, with a higher prevalence of use reported in Canada compared to the USA, New Zealand, and Australia. Notably, an estimated 19% of respondents reported lifetime use of one of the four substances studied.

Policy and Research Implications

The study underscores the urgent need for more robust clinical trials to explore the therapeutic potential of psychedelics safely. Current legal provisions and clinical trials are not keeping pace with consumer interest, which may lead to increased unregulated use. This gap highlights the necessity for clearer therapeutic use guidelines to ensure safe and effective patient access. Policymakers and researchers must work collaboratively to address this growing demand and bridge the gap between consumer interest and regulated medical use.

Risks and Unknowns

One of the key concerns raised by the study is the potential for adverse health effects resulting from unsupervised psychedelic use. Over a third of respondents who used psychedelics in the past year reported experiencing adverse events. This finding emphasizes the risks associated with self-initiated use, particularly when access to these substances is through nonregulated pathways. The lack of medical supervision and guidance can increase the likelihood of negative outcomes, underscoring the need for more comprehensive research and safety protocols.

Looking Forward

As interest in the therapeutic use of psychedelics continues to grow, it is crucial for the scientific community, healthcare providers, and policymakers to collaborate in developing a framework that supports safe and informed use. Future research should focus on understanding the dual motivations for psychedelic use and the factors contributing to adverse events. By expanding clinical trials and establishing clear guidelines, stakeholders can ensure that individuals seeking therapeutic benefits from psychedelics can do so safely and effectively.